Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer
Wang M., Zhang W., Cheng G., Xu J., Qu P.
Prospective Study with a reported sample of 61, published in Open Med (Wars) (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Open Med (Wars) (2025)
- Reported sample size
- 61
- Source database
- Europe PMC
- PMID
- 40918161
- PMCID
- PMC12413797
- DOI
- 10.1515/med-2025-1266
Abstract (original English)
Background The exosomal microRNAs (exomiRNAs) are promising novel biomarkers for clinical detection and prognosis assessment of human cancers. The aim of this study was to identify potential exomiRNAs as biomarkers in ovarian cancer (OC). Methods The candidate exomiRNAs were screened by analysis of GSE235525, GSE239685, and GSE216150 datasets and further validated in exosome samples from the serum of 61 patients with OC and OC cell lines by qPCR. The correlations between exomiRNAs expression and clinicopathological features of OC patients were assessed, and Kaplan-Meier survival and receiver operating characteristic curves were employed to analyze the prognostic and diagnostic values. Results We found that exomiR-188-3p expression was downregulated in patients with OC and OC cell lines compared with healthy controls and normal cells. Decreased exomiR-188-3p was associated with advanced FIGO stage, lymph node metastasis, and distant metastasis. The area under the curve (AUC) values of exomiR-188-3p for differentiating OC, stage IA-IIA OC, and no metastatic OC from healthy controls were 0.8983, 0.8461, and 0.8179. And combination of exomiR-188-3p and CA125 yields better diagnostic efficacy, with AUC values of 0.9323, 0.8925, and 0.9120. Lower expression of exomiR-188-3p predicted a poor overall survival and progression-free survival in patients with OC. Conclusion Decreased exomi
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.